Healthcare Realty Trust Incorporated

HR · NYSE

Market closed$21.32$0.030000 (+0.14%)After hours $21.32 · 0.00%

Key statistics

Previous close$21.29
Open$21.46
Day high$21.47
Day low$21.15
52-week high$21.47
52-week low$15.29
Market cap7.48B
Volume3.53M
Average volume4.30M
P/E ratio13.08
Forward P/E14.60
EPS1.63
Dividend yield+4.50%

Market context

Why it moved

HR's modest uptick today reflects resilience amid a broad market selloff driven by a chip stock rout and geopolitical tensions stemming from U.S. strikes on Iranian military targets, as investors rotated away from high-volatility tech sectors into more defensive real estate and staffing-related equities.

What is happening

Recent company-specific developments and publisher coverage.

July 17, 2026Healthcare Realty Trust closed essentially flat as the stock touched a fresh 52-week high of $21.47 intraday, reflecting meaningful momentum from its recent recovery — shares have climbed sharply from a 12-month low of $15.28. The stock is benefiting from strong sector tailwinds: U.S. personal healthcare spending hit $3.7 trillion in May 2026, peer Welltower raised full-year guidance on robust senior housing demand, and Ventas lifted its annualized dividend 8.3%. Analyst sentiment on HR remains mixed (consensus Hold, average target $21.67), though Scotiabank upgraded to Outperform in May with a $22 target, and a new institutional position from AMG National Trust Bank underscores growing investor interest as the broader healthcare REIT sector outperforms a volatile equity market.

0.1409

July 16, 2026Healthcare Realty Trust rose sharply, touching a fresh 52-week high of $21.29, as investor enthusiasm around healthcare REITs builds on the back of favorable sector dynamics and improving company fundamentals. The stock has surged roughly 35% over the past year, supported by Q1 earnings that beat EPS estimates ($0.41 vs. $0.39 consensus), an upward revision to full-year FFO guidance ($1.59–$1.65), and strategic capital raises including a $400M term loan and $600M in exchangeable notes. A softer-than-expected June CPI reading has also boosted rate-sensitive REITs broadly, while peer Ventas lifting its dividend 8.3% reinforced positive sentiment across healthcare real estate.

3.0993

July 15, 2026Healthcare Realty Trust edged lower, closing down about 1.1%, as the real estate sector (XLRE) also retreated while the broader S&P 500 finished near flat after rallying on a cooler-than-expected June CPI report. Analyst sentiment on HR remains mixed, carrying a consensus Hold rating and an average price target of $21.67 — modestly above current levels — while a recent insider transaction drew attention: CAO Amanda Callaway sold roughly 19% of her stake in late June. On the institutional side, AMG National Trust Bank initiated a new $1.97 million position in Q1, and Scotiabank raised its price target to $22 with an Outperform rating in May, signaling selective optimism for the healthcare REIT as investors await Q2 earnings.

-1.1489

July 15, 2026Healthcare Realty Trust closed modestly higher, touching a fresh 52-week high of $20.95 intraday, as the outpatient medical REIT continues to build on a 25% year-to-date gain fueled by positive analyst momentum and strong fundamentals. Multiple brokerages including JPMorgan and Wells Fargo recently raised price targets to $21, while Cantor Fitzgerald holds an Overweight with a $22 target after the company beat Q1 EPS estimates ($0.41 vs. $0.39 expected) and raised its FY2026 FFO guidance to $1.59–$1.65. The stock also benefits from a 4.6% dividend yield backed by 34 consecutive years of payments and recent capital market moves including a $600M exchangeable notes offering and a $400M term loan facility.

0.3844

July 14, 2026Healthcare Realty Trust edged higher after touching a new 52-week high of $20.93 intraday, extending a strong year-to-date run of roughly 25% gains amid favorable conditions for medical office REITs. The move was supported by recent positive catalysts including Cantor Fitzgerald raising its price target to $22 with an Overweight rating following strong Q1 results and raised full-year FFO guidance of $1.59–$1.65, as well as the company's $400 million term loan facility and $600 million exchangeable senior notes offering. Despite a broadly weaker equity market today — weighed down by renewed U.S.-Iran tensions and rising oil prices — Healthcare Realty Trust's defensive REIT profile and 4.6% dividend yield helped attract investors seeking shelter, even as some valuation concerns linger.

0.58

July 11, 2026Healthcare Realty Trust closed essentially unchanged, brushing up against its 52-week high of $20.90, as investors position ahead of its Q2 2026 earnings release scheduled for July 30. Analyst sentiment has been constructive, with JP Morgan raising its price target to $21.00 and Cantor Fitzgerald maintaining an 'Overweight' rating with a $22.00 target, while UBS also nudged its target to $21.00. Supporting the backdrop, UBS highlighted dividend-paying healthcare REITs ahead of earnings citing healthy senior housing and skilled nursing fundamentals, and the broader REIT sector has outperformed the equity market in the first half of 2026.
July 9, 2026Healthcare Realty Trust edged modestly higher, closing near its 52-week high of $20.90 as positive analyst momentum builds ahead of its Q2 2026 earnings release scheduled for July 30. Both JP Morgan and UBS raised their price targets to $21 this week, while Cantor Fitzgerald carries an Overweight rating with a $22 target. Institutional interest is also growing, with HSBC, Aberdeen, and Jupiter Asset Management among those adding positions recently. The broader real estate sector has shown resilience in 2026, with REITs outperforming the broader equity market at mid-year — a tailwind for HR despite ongoing geopolitical volatility from U.S.-Iran tensions weighing on rate expectations.

0.2908

July 9, 2026Healthcare Realty Trust closed essentially flat, hovering near its 52-week high of $20.90 amid a broader risk-off session driven by U.S.-Iran ceasefire breakdown and rising Treasury yields. Investors are focused on the company's upcoming Q2 2026 earnings release scheduled for July 30, after Q1 beat EPS estimates at $0.41. Institutional interest remains mixed—while SG Americas cut its stake sharply, Invesco and Amundi significantly increased positions in Q2, and UBS recently raised its price target to $21 with a Neutral rating, reflecting cautious optimism around the medical outpatient building REIT.

-0.0969

Stock Titan · July 7, 2026Healthcare Realty Trust schedules Q2 results, call for July 31GlobeNewswire · July 7, 2026Healthcare Realty Trust Announces Second Quarter Earnings Release Date and Conference CallLatham & Watkins LLP · May 6, 2026Latham & Watkins Advises Healthcare Realty in US$600 Million Exchangeable Senior Notes OfferingGlobeNewswire · May 5, 2026Healthcare Realty Announces Pricing of Upsized $600 Million Exchangeable Senior Notes Offering
Benzinga · July 9, 2026JP Morgan Maintains Neutral on Healthcare Realty Trust, Raises Price Target to $21
Benzinga · July 8, 2026UBS Maintains Neutral on Healthcare Realty Trust, Raises Price Target to $21
Mt Newswire · June 23, 2026Healthcare Realty Trust Insider Sold Shares Worth $524,874, According to a Recent SEC Filing
Benzinga · June 17, 2026Raymond James Reinstates Outperform on Healthcare Realty Trust, Announces $24 Price Target
Benzinga · June 1, 2026Wells Fargo Maintains Equal-Weight on Healthcare Realty Trust, Raises Price Target to $21
Benzinga · May 14, 2026RBC Capital Maintains Sector Perform on Healthcare Realty Trust, Raises Price Target to $21
Mt Newswire · May 14, 2026RBC Raises Price Target on Healthcare Realty Trust to $21 From $19, Keeps Sector Perform Rating
Benzinga · May 13, 2026UBS Maintains Neutral on Healthcare Realty Trust, Raises Price Target to $20

Peers